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S U M M A R Y
Human parechovirus (HPeV) belongs to the Picornaviridae family of RNA viruses. HPeV infections can be
asymptomatic, lead to mild respiratory and/or gastrointestinal symptoms, or less frequently cause
severe diseases such as sepsis, meningitis, encephalitis, and myocarditis. Severe neurological HPeV
infections occur most commonly in infants and neonates. There are currently 16 recognized types of
HPeV. HPeV type 3 (HPeV3) has been the predominant type associated with severe central nervous
system disease in neonates and newborns since its discovery in 1999. Although HPeV-related infections
have been reported in adults, symptomatic HPeV3 infections in adolescents and adults are uncommon. A
case of severe HPeV3 myocarditis and encephalitis in an adolescent is described.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Human parechovirus (HPeV), ﬁrst isolated in 1956, is a positive-
sense, single-stranded RNA virus of the family Picornaviridae and one
of three species in the genus Parechovirus. There are currently
16 known HPeV types, which can cause a variety of diseases.
Whereas HPeV3 is known to cause serious infections in neonates and
infants, including sepsis, meningitis, and encephalitis, severe HPeV3
central nervous system (CNS) infections in adolescents and adults
are rare.1 A case of severe HPeV3 myocarditis and encephalitis in an
adolescent that is of epidemiological signiﬁcance is reported below.
2. Case report
A 16-year-old female with a history of systemic lupus
erythematosus (SLE) diagnosed at age 10 years, presented to the* Corresponding author.
http://dx.doi.org/10.1016/j.ijid.2015.05.008
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hospital with chest pain and dyspnea. The previous diagnosis of
SLE was supported by positive antibodies (ANA, Smith/RNP, and
double-stranded DNA) and clinical arthritis, and biopsy-conﬁrmed
class IV lupus nephritis. The patient also had prolonged
hypogammaglobulinemia secondary to rituximab. A chest X-ray
revealed cardiomegaly and a small right-sided pleural effusion.
Echocardiography indicated the presence of biventricular dysfunc-
tion and a systolic ejection fraction of 13%. A cardiac biopsy
showed active myocarditis (Figure 1A). The myocardial tissue
tested negative for parvovirus B19 and herpes simplex virus, but
positive for HPeV using a real-time reverse-transcription PCR (RT-
PCR) assay that detects all known members of the genus
Parechovirus.2 In situ hybridization demonstrated HPeV in cardiac
myocytes (Figure 1B). The patient received intravenous immuno-
globulin (IVIG) therapy (two doses of 37.5 g and two doses of 40 g)
over a period of 3 weeks. During the subsequent 2 months, she
regained normal cardiac function and was discharged.
One year later, the patient presented with a subacute onset of
dizziness, unsteady gait, declining academic performance, fatigue,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Hematoxylin and eosin staining of the heart showing active myocarditis (A). In situ stain for human parechovirus demonstrating the presence of viral RNA within
cardiomyocytes (arrow) (B). MRI showing abnormal bilateral hyperintense signals (arrows) on T2/FLAIR sequences in periventricular white matter (C), and cerebral
peduncles (D).
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5 months. When her symptoms progressed to include slowed
speech, difﬁculty performing executive functions, truncal ataxia,
and a positive Romberg sign, the patient was admitted to the
regional children’s hospital. The differential diagnosis for her
neurological symptoms was broad. Lupus cerebritis and demye-
linating disease were ruled out clinically. Cerebrospinal ﬂuid (CSF)
examination demonstrated normal glucose and protein levels with
no pleocytosis, and testing was negative for viral pathogens,
including adenovirus, astrovirus, norovirus, rotavirus, sapovirus,
enterovirus, parvovirus B19, herpes simplex virus, varicella zoster
virus, Epstein–Barr virus, JC virus, and West Nile virus. CSF
bacterial cultures were also negative. Liver function tests showed a
mild elevation in alkaline phosphatase and alanine aminotrans-
ferase levels, which were not signiﬁcant enough to cause hepatic
encephalopathy. A serum sample tested positive for HPeV by PCR
during week 4 of the hospital admission. The CSF sample from the
ﬁrst day of admission was tested retrospectively for HPeV and was
positive, as was a stool sample.
During the ﬁrst 6 weeks of this admission, the patient’s
presenting symptoms persisted, and she developed an intention
tremor and head tremor. Next, she developed persistent urinary and
fecal incontinence. During week 7, the patient developed difﬁculty
swallowing and left-sided neglect. IVIG was administered 4 times
(4.3 g, 17.2 g, 17.2 g, and 30.1 g) during weeks 8 and 9, while serum
HPeV status was monitored until resolution of viremia. A repeat
lumbar puncture was performed, and the CSF tested negative for
HPeV. However, the patient continued to worsen clinically,
becoming progressively weaker from weeks 8 to 12.
After week 12 of admission, the patient was transferred to our
hospital. At the time of transfer, the patient could not move any ofher extremities and had bilateral ophthalmoplegia. A brain MRI
showed T2/FLAIR signal abnormalities in the periventricular white
matter and brainstem (Figures 1C and 1D). The patient was
admitted to the neurology intensive care unit and started on high-
dose methylprednisolone 1 g intravenously every 6 h. Evaluation
by rheumatology concluded her state was not consistent with
lupus cerebritis. A paraneoplastic syndrome antibody panel and
angiotensin-converting enzyme level were within normal limits.
Her neurologic examination improved over the course of 2 weeks.
Steroid therapy was changed to prednisone 40 mg/day, tapered to
20 mg/day, and she was discharged to an acute care facility.
Two months following discharge, the patient was re-admitted
to the hospital for further neurological evaluation and IVIG
treatment. On examination, she was quadriparetic with upper
motor neuron examination ﬁndings. An echocardiogram showed
an ejection fraction of 18%. Brain MRI demonstrated interval
progression of the abnormal changes predominantly involving the
corticospinal tracts. Analysis of CSF obtained during this admission
was positive for HPeV. Complete VP1 gene sequencing (GenBank
accession number KP772256) of this sample identiﬁed the virus as
HPeV3, and the VP1 protein sequence was found to contain ﬁve
unique amino acid substitutions that differ from recent (2009–
2014) consensus HPeV3 protein sequences found in GenBank or
sequenced at the US Centers for Disease Control and Prevention
since 2009.3 During this admission the patient received a 7-day
course (15 g/24 h) of IVIG for a total of 105 g. The patient’s motor
strength was noted to improve, but her cardiac function did not
improve; an echocardiogram prior to discharge demonstrated the
ejection fraction was still low (18%). The patient was discharged to
an acute care facility where she remained for 7 months and
demonstrated gradual improvement in motor function. She has
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physical rehabilitation twice a week, and continues to improve.
3. Discussion
After enterovirus, HPeV is considered the second most common
cause of viral meningitis in young children.4 While not common in
adults, severe HPeV infections have been reported in a 35-year-old
with an inﬂuenza-like illness and a 78-year-old who died of
pneumonia.5,6 Additionally, an outbreak of HPeV1-related acute
ﬂaccid paralysis in Jamaica affected six patients of ages 1–27
years.7 An outbreak of epidemic myalgia among adults (ages 25–66
years) in Japan was shown to be HPeV3-associated in 14 patients.8
Infections with HPeV including HPeV3 have been described in
adults, but HPeV3 infections occur mostly in children under
2 months of age.9 Of all the HPeV types, HPeV3 has the strongest
association with severe neurological illness. Cardiomyopathy and
suspected HPeV1 myocarditis has been reported in a 5-month-old
boy; however, no case of HPeV3 myocarditis has been documented
prior to this report.10
The CSF ﬁndings, abnormalities on brain MRI, and clinical
features in this adolescent with HPeV3 encephalitis are similar to
those described in infants and neonates with HPeV3 encephalitis.
CSF from this patient showed normal protein and glucose levels
with no pleocytosis. Verboon-Maciolek et al. reported CSF
pleocytosis in only one of 10 neonatal cases of HPeV3 encephalitis,
and all 10 cases showed normal CSF protein and glucose levels.11
Verboon-Maciolek et al. also reported seizures in nine of 10 infants
with HPeV infection. While this patient did not have continuous
electroencephalography (EEG) monitoring, episodes of seizure
activity were observed.
Most picornaviral infections are controlled through humoral
immunity. It is not surprising, therefore, that a patient with
hypogammaglobulinemia such as this patient would be particu-
larly susceptible to a severe HPeV3 infection. This patient’s
improvement after IVIG therapy conﬁrms the utility of this
intervention. The demonstration of HPeV RNA in the cytoplasm of
cardiomyocytes suggests direct infection of these cells resulting in
myocarditis. The resultant cardiac myocyte injury could be caused
directly as a consequence of viral replication, indirectly via a cell-
mediated immune response, or both. Whereas the myocarditis
may represent a degree of cellular immune response, this patient’s
deﬁciency of humoral immunity promoted the establishment of a
chronic HPeV3 infection with eventual spread to the CNS. The
mechanisms of HPeV3-mediated cellular injury in the CNS,
however, are currently unknown. Additionally, the high number
of ﬁve unique amino acid substitutions identiﬁed in the VP1protein of this virus compared to other contemporary HPeV3
strains may be explained by persistence of the virus and prolonged
viral replication in this patient over at least 2 years. The clinical
signiﬁcance of these genetic changes on the behavior of this virus is
not known, but could include altered sensitivity to IVIG therapy
and changes in tissue tropism.
Serious HPeV3-related diseases, including encephalitis and
myocarditis, may be more common than currently documented
since this virus is not routinely tested for after infancy. This patient
was identiﬁed as having HPeV primarily because she was initially
hospitalized at a children’s hospital that routinely screens for HPeV
in cases of encephalitis. The differential diagnoses for both
encephalitis and myocarditis, especially in immunocompromised
patients, regardless of age, should be expanded to include HPeV3
infection. While therapy is extremely limited for HPeV3 infections,
identiﬁcation of these infections would allow for the option to
initiate IVIG therapy. Additionally, establishing routine testing for
HPeV in adolescent and adult patients with encephalitis and/or
myocarditis will provide critical data regarding the true epidemi-
ology of this emerging infection.
Conﬂict of interest: None.
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